The scientific focus adapted
to express the optimum potential
of your molecule

Marketing:
Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Discovery:
Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Previous news

2019

05/17/2019 87th EAS Congress (May 26-29, 2019) in Maastricht, Netherlands

Physiogenex will attend the 2019 EAS Congress on May 26-29, 2019 in Maastricht. Dr. François Briand, our Director of Research and Business Development, will be present at this event. He will be happy to discuss with you about your preclinical atherosclerosis projects. Please Contact us if you wish to set up an appointment. About us […]

Read more

04/08/2019 Keystone Symposia Immunometabolism, Metaflammation and Metabolic Disorders, (April 14-18, 2019) in Vancouver, British Columbia.

Physiogenex will be present at the Keystone Symposia  Immunometabolism, Metaflammation and Metabolic Disorders meeting on April 15th, 2019 during the session poster 1 (7.30 pm- 10 pm) Dr. François Briand, our Director of Research and Business Development, will present a poster dealing with our innovative NASH models: ID 1014: “GLP-1 receptor agonists reduce liver inflammation […]

Read more

04/03/2019 The International Liver Congress – Annual EASL meeting (April 10-14, 2019), in Vienna, Austria.

Physiogenex will attend The International Liver Congress on April 12, 2019 during the Poster Session NAFLD: Experimental and pathophysiology  (9am – 5pm). Dr. François Briand, our Director of Research and Business Development, will present a poster dealing with our NASH models. Poster (#4725)  The benchmarks obeticholic acid and elafibranor show variable effects on NASH and […]

Read more

02/25/2019 Keystone Unraveling the Secrets of Kidney Disease (March 3-7, 2019), in Whistler, British Columbia, Canada.

Physiogenex will attend the Keystone Unraveling the Secrets of Kidney Disease meeting on March 4th, 2019 during the Poster Session 1 (19:30 – 22:00). Dr. François Briand, our Director of Research and Business Development, will present a poster dealing with our Diabetic Nephropathy models. Poster (#1002)  SGLT2 inhibitor dapagliflozin reduces hyperfiltration and prevents glomerular filtration […]

Read more

01/02/2019 Physiogenex to present at the NASH-TAG 2019

Physiogenex will present at the NASH-TAG 2019 in Park City, UT, USA, January 3rd-5th, 2019. Dr. François Briand, Director of Research and Business Development, will be presenting one poster dealing with Physiogenex NASH animal models, and a second poster dealing with the measurement of alpha-SMA protein levels in NASH/fibrosis models, using a HTRF assay kit developed […]

Read more

2018

11/29/2018 Physiogenex to present radiotracer-based hyperinsulinemic euglycemic clamp studies and diabetic nephropathy models at the WCIR 2018 in Los Angeles, CA, USA

Physiogenex will be presenting radiotracer-based hyperinsulinemic euglycemic clamp studies and diabetic nephropathy models at the World Congress of Insulin Resistance (WCIR) 2018, in Los Angeles, CA, USA, November 29th – December 1st, 2018. The abstracts will be presented by Dr. François Briand, Director of Research and Business Development, during the poster session on Thursday, November 29th, 6:30pm-7:30pm. […]

Read more

11/14/2018 Physiogenex to present the effects of green coffee and green tea in DIO mice at Obesity Week 2018 in Nashville, TN, USA

Physiogenex will be presenting the effects of green coffee and green tea at the Obesity Week 2018, in Nashville, TN, USA, November 11-15th, 2018. The study will be presented by Dr. François Briand, Director of Research and Business Development, during the poster session on Wednesday, November 14th, 12:00am-1:30pm, poster#3409. See the abstract If you want to set […]

Read more

11/08/2018 Physiogenex to present its 3-week ultra-fast NASH screening mouse model at the AASLD Liver Meeting 2018

Physiogenex will be presenting its 3-week ultra-fast NASH screening mouse model mouse at the Liver Meeting 2018, in San Francisco, November 9th-13th, 2018. The effects of GLP-1 receptor agonists in this innovative NASH mouse model will be presented by Dr. François Briand, Director of Research and Business Development, during the poster session on Sunday, November 11th, 12:30am-2:00pm, poster#1827. If you want […]

Read more

10/26/2018 Physiogenex and its industry partners to present at the ASN Kidney Week 2018, October the 27th, 2018, San Diego, CA, USA.

Physiogenex will be presenting its innovative animal models of diabetic nephropathy, namely the db/db mouse on high protein diet and the Unx/salt supplemented SDT fatty rat, at the ASN Kidney Week 2018, in San Diego, California. The studies, performed by Physiogenex and industry partners Novo Nordisk, Scohia Pharma and CLEA Japan Inc., will be presented […]

Read more

10/07/2018 Physiogenex to present at the Keystone Conference on Drivers of Type 2 Diabetes in Seoul, Korea – October 7-12th, 2018

Physiogenex will be presenting a hyperinsulinemic euglycemic clamp study differentiating insulin analogues in STZ-rats, a model of experimental diabetes. The study will be presented by Dr. François Briand, Director of Research and Business Development, during the poster session 1, on Monday October the 8th, poster #1012. If you wish to make an appointment during the […]

Read more

06/23/2018 Physiogenex to present at the American Diabetes Association Scientific Sessions in Orlando, FL, USA, June 22nd -26th 2018

Physiogenex will be presenting a hyperinsulinemic euglycemic clamp study differentiating insulin analogues in STZ-rats, a model of experimental diabetes. The study will be presented by Dr. François Briand, Director of Research and Business Development, during the ADA 2018 poster session, on Monday June the 25th, from noon to 1pm, poster #1773-P. If you wish to […]

Read more

06/10/2018 Physiogenex to present at the XVIIIth International Symposium on Atherosclerosis in Toronto, Canada, June the 9th-12th, 2018

During the poster session, Physiogenex will be presenting a study dealing with the effects of evolocumab, an anti-PCSK9 antibody, in the Golden Syrian hamster model. Another study dealing with the effects of obeticholic acid on atherosclerosis and NASH in LDL-r KO mice will be presented by Dr. François Briand, Director of Research and Business Development, […]

Read more

04/26/2018 Physiogenex, Iris Pharma and CLEA Japan to present the features of diabetic retinopathy in the Uni-nephrectomized SDT fatty rat model at ARVO 2018, Honolulu, Hawaii

Physiogenex, Iris Pharma and CLEA Japan will be presenting the features of diabetic retinopathy in the Uni-Nephrectomized SDT Fatty Rat, a novel Type 2 diabetic model of Diabetic Nephropathy, at the Association for Research in Vision and Ophtalmology 2018 conference (ARVO 2018) in Honolulu, Hawaii, USA. Through their partnership, Physiogenex, Iris Pharma and CLEA Japan Inc., have […]

Read more

01/05/2018 Physiogenex to present its NASH hamster model at NASH-TAG 2018

Physiogenex will present at the NASH-TAG 2018 in Park City, UT, USA, January 4th-6th, 2018. Dr. François Briand, Director of Research and Business Development, will be presenting a poster about the effects of obeticholic acid and elafibranor in the Diet-Induced NASH (DIN) hamster model. Looking forward to meet you there! About Physiogenex Physiogenex is a leading […]

Read more

2017

11/08/2017 Physiogenex to present its NASH models at EASL NAFLD Summit 2017

Physiogenex will present at the EASL NAFLD Summit in Rome, Italy, November 9th-11th, 2017. Dr. François Briand, Director of Research and Business Development, will be presenting an e-poster about the effects of obeticholic acid in various Physiogenex preclinical NASH models, during the e-poster session 3, Nov. the 9th, 08:00pm-08:20pm. If you wish to further discuss about […]

Read more

10/30/2017 Physiogenex and CLEA Japan Inc. to present at the Kidney Week 2017, Oct. 31st- Nov. 5th, 2017, New Orleans, LA, USA.

Dapagliflozin Alone or Combined with Ramipril Improves Hyperglycemia and Hypertension and Prevents Kidney Complications and GFR Decline in the Nephrectomized SDT Fatty Rat Model of Diabetic Nephropathy. Read the abstract Through their partnership put in place in January 2016, Physiogenex and CLEA Japan Inc. have worked thoroughly to set-up and validate a novel rat model […]

Read more

10/09/2017 Physiogenex will be at the AASLD Liver Meeting 2017

Physiogenex will be attending the AASLD Liver Meeting 2017 in Washington DC, October 20th-24th, 2017. If you wish to know more about our preclinical NASH models to optimize your preclinical drug development program, please contact us to set-up an appointment with Dr. François Briand, Director of Research and Business Development during the Liver meeting. We […]

Read more

06/10/2017 Physiogenex presents the effects of SGLT2 inhibition and glucagon on intestinal cholesterol absorption at ADA 2017, San Diego, USA

Physiogenex has investigated the acute effects of SGLT2 inhibition and glucagon on intestinal cholesterol absorption in the Golden Syrian hamster model. Dr. François Briand, Director of Research and Business Development at Physiogenex, will present the study results during the 77th American Diabetes Association 2017 scientific sessions in San Diego, CA, USA. The oral presentation is scheduled during the oral […]

Read more

06/04/2017 Physiogenex and CLEA Japan Inc. present the benefits of SGLT2 inhibitor dapagliflozin on their 10-week rat model for evaluating drugs targeting Diabetic Nephropathy at ERA-EDTA 2017 congress in Madrid, Spain

Through their partnership put in place in January 2016, Physiogenex and CLEA Japan Inc. have worked thoroughly to set-up and validate a novel rat model for evaluating drugs targeting Diabetic Nephropathy. The Spontaneously Diabetic Torii fatty (SDT fatty) rat, a model of obesity type 2 diabetes distributed by CLEA Japan Inc. since 2012, has been […]

Read more

05/19/2017 Physiogenex and CLEA Japan Inc. present the benefits of SGLT2 inhibitor dapagliflozin on their 10-week rat model for evaluating drugs targeting Diabetic Nephropathy at EDNSG 2017 in Helsinki

Through their partnership put in place in January 2016, Physiogenex and CLEA Japan Inc. have worked thoroughly to set-up and validate a novel rat model for evaluating drugs targeting Diabetic Nephropathy. The Spontaneously Diabetic Torii fatty (SDT fatty) rat, a model of obesity type 2 diabetes distributed by CLEA Japan Inc. since 2012, has been […]

Read more

04/04/2017 Physiogenex and CLEA Japan Inc. present the benefits of SGLT2 inhibitor dapagliflozin on their 10-week rat model for evaluating drugs targeting Diabetic Nephropathy at the World Congress of Nephrology in Mexico

Through their partnership put in place in January 2016, Physiogenex and CLEA Japan Inc. have worked thoroughly to set-up and validate a novel rat model for evaluating drugs targeting Diabetic Nephropathy. The Spontaneously Diabetic Torii fatty (SDT fatty) rat, a model of obesity type 2 diabetes distributed by CLEA Japan Inc. since 2012, has been […]

Read more

02/28/2017 Physiogenex will present the effects of obeticholic acid in its novel Diet-Induced NASH (DIN) hamster model at the Keystone Symposium on Bile Acid Receptors as Signal Integrators in Liver and Metabolism, in Monterey, CA, USA, March 3-7, 2017.

Unlike rats and mice, the DIN hamster has a closer lipid/lipoprotein metabolism as compared to humans. In fact, it replicates the LDL increase and HDL lowering induced by obeticholic acid, as observed in clinical trials. This unique model to evaluate drugs targeting NASH will be presented by Dr. François Briand, Director of Research and Business […]

Read more

2016

12/01/2016 Physiogenex to present its Diet-Induced NASH (DIN) hamster and Unx/salt-supplemented SDT fatty rat models at the World Congress on Insulin Resistance (WCIR) 2016

Physiogenex is proud to present its Diet-Induced NASH (DIN) hamster and Unx/salt-supplemented SDT fatty rat models at the World Congress on Insulin Resistance (WCIR) 2016, in Los Angeles, December 1st-3rd, 2016. These  models will be presented by Dr. François Briand, Director of Research and Business Development, during the poster sessions. If you want to set an […]

Read more

11/18/2016 Physiogenex launches the Diet-Induced NASH (DIN) hamster, a unique model showing the same benefits and side effects of obeticholic acid observed in humans.

Physiogenex now provides the Diet-Induced NASH (DIN) hamster model, a unique model showing the same benefits and side effects (higher LDL-c, lower HDL-c) of obeticholic acid observed in humans. Compare to mouse models, this predictive model is a robust tool to evaluate novel compounds targeting NASH, in comparison with the benchmark obeticholic acid, a FXR agonist. […]

Read more

11/06/2016 Physiogenex and CLEA Japan Inc. to present at the Kidney Week 2016, Nov. 15-20th, 2016, Chicago, IL, USA.

Effects of the SGLT2 inhibitor dapagliflozin in the salt-supplemented/uni-nephrectomized SDT fatty rat, a novel 10-week rat model for evaluating drugs targeting Diabetic Nephropathy. Read the abstract Through their partnership put in place in January 2016, Physiogenex and CLEA Japan Inc. have worked thoroughly to set-up and validate a novel rat model for evaluating drugs targeting […]

Read more

10/29/2016 Physiogenex to present its Diet-Induced NASH (DIN) mouse and hamster models at the liver meeting 2016

Physiogenex is proud to present its Diet-Induced NASH (DIN) mouse and hamster models at the Liver Meeting 2016, in Boston, November 11th-15th, 2016. These NASH models will be presented by Dr. François Briand, Director of Research and Business Development, during oral parallel sessions and late-breaking abstracts poster session as below: -Parallel 20 (Steatohepatitis:  Experimental I): […]

Read more

01/19/2016 Physiogenex starts collaboration with CLEA Japan, Inc.

Labège, France ; Tokyo, Japan ; January, 19th, 2016 – Physiogenex, a leading preclinical contract research organization specializing in metabolic diseases and complications, has signed a partnership with CLEA Japan Inc, a reknowned Japanese company with long term experience in bioservices, such as experimental rodents supply to pharmaceutical companies.

Read more

2015

2014

2013

03/04/2013 A new study demonstrates that Partial Inhibition of Adipose Tissue Lipolysis Improves Glucose Metabolism and Insulin Sensitivity.

A study published in PLOS one demonstrates that HSL haploinsufficiency and treatment with a HSL inhibitor resulted in improvement of insulin tolerance without impact on body weight, fat mass, and WAT inflammation in high-fat-diet–fed mice.

In this study, Physiogenex provided its expertise with the in vivo whole body free fatty acids turnover experiment. Analysis revealed that blunted lipolytic capacity was associated with diminution in FA uptake and storage in peripheral tissues of obese HSL haploinsufficient mice.

Read more

2012

11/22/2012 Physiogenex publishes his alternative and novel method to measure in vivo reverse cholesterol transport (oxLDL-RCT)

In a recent study published online in Arteriosclerosis, Thrombosis, and Vascular Biology on November 8, 2012,  the effects of CETP inhibition on in vivo reverse cholesterol (RCT) transport were investigated in a diet-induced hamster model of metabolic syndrome.

In this study, the “ox-LDL-RCT method” (Briand et al / Physiogenex SAS) , which is based on the injection of 3H-cholesteryl-oleate–labeled/oxidized LDL particles, was developed and used as an alternative and novel method to measure RCT.

Read more

06/26/2012 Physiogenex strengthens its offer through a strategic partnership with GAIA nuclear imaging platform.

Physiogenex and the Gamma Imaging Applications Platform (GAIA) signed a strategic partnership to work jointly on preclinical studies exploiting GAIA‘s nuclear molecular imaging facilities and expertise.

The various services offered to clients will include:

  • Radioactive tagging of molecules of interest
  • Biodistribution of orginal molecules and pharmakinetics
  • The evaluation of the efficiency of new therapeutic molecules with validated radiotracers
  • Characterization of an animal model of interest.
Read more

2011

09/01/2011 A new study demonstrates that the CETP inhibitor anacetrapib promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model.

 Using independent approaches to assess cholesterol metabolism (macrophage-to-feces reverse cholesterol transport, HDL-cholesteryl esters kinetics and measurement of bulk cholesterol and bile acids in feces), this study supports the development of the CETP inhibitor anacetrapib as a novel lipid therapy for the treatment of dyslipidemia and atherosclerosis.

Read more

2010

2009

2008